ATE305040T1 - Pge synthase und verfahren und mitteln zur modulation deren aktivität - Google Patents

Pge synthase und verfahren und mitteln zur modulation deren aktivität

Info

Publication number
ATE305040T1
ATE305040T1 AT99957275T AT99957275T ATE305040T1 AT E305040 T1 ATE305040 T1 AT E305040T1 AT 99957275 T AT99957275 T AT 99957275T AT 99957275 T AT99957275 T AT 99957275T AT E305040 T1 ATE305040 T1 AT E305040T1
Authority
AT
Austria
Prior art keywords
activity
pge synthase
modulating
pge
synthase
Prior art date
Application number
AT99957275T
Other languages
German (de)
English (en)
Inventor
Per-Johan Jakobsson
Bengt Samuelsson
Ralf Morgenstern
Anthony Ford-Hutchinson
Joseph Mancini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE305040T1 publication Critical patent/ATE305040T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
AT99957275T 1998-11-09 1999-11-02 Pge synthase und verfahren und mitteln zur modulation deren aktivität ATE305040T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10768798P 1998-11-09 1998-11-09
PCT/EP1999/008363 WO2000028022A1 (en) 1998-11-09 1999-11-02 Pge synthase and methods and means for modulating its activity

Publications (1)

Publication Number Publication Date
ATE305040T1 true ATE305040T1 (de) 2005-10-15

Family

ID=22317930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957275T ATE305040T1 (de) 1998-11-09 1999-11-02 Pge synthase und verfahren und mitteln zur modulation deren aktivität

Country Status (9)

Country Link
US (4) US6395502B1 (enExample)
EP (1) EP1129188B1 (enExample)
JP (2) JP4503849B2 (enExample)
AT (1) ATE305040T1 (enExample)
AU (1) AU770307B2 (enExample)
CA (1) CA2349529C (enExample)
DE (1) DE69927400T2 (enExample)
ES (1) ES2249042T3 (enExample)
WO (1) WO2000028022A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität
WO2001057225A1 (fr) * 2000-02-03 2001-08-09 Chugai Seiyaku Kabushiki Kaisha Proteine regissant l'activite de la pge2 synthase et son utilisation
AU2002323358A1 (en) * 2001-08-24 2003-03-10 Karoliska Innovations Ab Methods for preparing purified prostaglandin e synthase
IL161831A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Disruption of the prostaglandin e synthase 2 gene
EP1575498A2 (en) * 2002-09-25 2005-09-21 Pharmacia Corporation Antisense modulation of microsomal prostaglandin e2 synthase expression
WO2004067766A1 (en) * 2003-01-27 2004-08-12 Pfizer Products Inc. Novel methods involving the determination of activity of enzymes that use or produce prostaglandin endoperoxide h2
WO2005024059A2 (en) * 2003-09-09 2005-03-17 Karolinska Innovations Ab Methods for identifying compounds for inhibiting fever
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
CA2639412A1 (en) * 2007-09-11 2009-03-11 Universite Laval Prostaglandin e2 modulation and uses thereof
CN117323320B (zh) * 2023-11-20 2025-10-31 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US914356A (en) * 1901-11-30 1909-03-02 Harry Ward Leonard Electric-circuit controller.
EP1015624A2 (en) * 1997-09-17 2000-07-05 The Johns Hopkins University P53-induced apoptosis
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität

Also Published As

Publication number Publication date
CA2349529C (en) 2009-10-27
US7192733B2 (en) 2007-03-20
DE69927400D1 (de) 2006-02-02
US7067296B2 (en) 2006-06-27
US20030064493A1 (en) 2003-04-03
AU1504100A (en) 2000-05-29
JP2002539762A (ja) 2002-11-26
US6395502B1 (en) 2002-05-28
JP4503849B2 (ja) 2010-07-14
WO2000028022A1 (en) 2000-05-18
AU770307B2 (en) 2004-02-19
US7645601B2 (en) 2010-01-12
CA2349529A1 (en) 2000-05-18
EP1129188A1 (en) 2001-09-05
JP2010115205A (ja) 2010-05-27
ES2249042T3 (es) 2006-03-16
EP1129188B1 (en) 2005-09-21
DE69927400T2 (de) 2006-06-29
US20050118696A1 (en) 2005-06-02
US20080153107A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2001038532A3 (en) Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
ATE537264T1 (de) Verfahren und zusammensetzungen für die gerichtete mikrowellenchemiie
AU7301898A (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE69919151D1 (de) Verfahren zur synthese von cox-2 inhibitoren
BR9707948A (pt) Processo para obter plantas transplastômicas
ATE191934T1 (de) Verfahren zur isothermer amplifikation von nukleinsäure molekülen
ATE551352T1 (de) Peptidakzeptorbindungsverfahren
DE60213803D1 (en) Happier mapping
DE69927400D1 (de) Pge synthase und verfahren und mitteln zur modulation deren aktivität
ATE536372T1 (de) Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung
DE50114193D1 (de) Verfahren zur identifizierung von substanzen, die die aktivität von hyperpolarisations-aktivierten kationen-kanälen modulieren
DE69431564D1 (de) Reagenz zur behandlung von arthritischen zustaenden
DE69823372T8 (de) Verfahren und reagentiensatz zur amplifizierung, sequenzierung und typisierung von hla i genen
ATE344321T1 (de) Verfahren zur aufreinigung von bakterienzellen und zellbestandteilen
WO2005060722A3 (en) Modulation of immune system function by modulation of polypeptide arginine methyltransferases
ATE212382T1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung
AR020191A1 (es) Aparato y metodo para medir amoniaco en procesos bioquimicos
ATE489478T1 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
ATE421090T1 (de) Neues screening-verfahren von modulatoren der bakteriellen transkription
DE60227335D1 (de) Kontinuierliches Verfahren zur Modifizierung von Stärke und Stärkederivate mittels Verzweigungsenzyme
AU2002361162A1 (en) Evanescence-based multiplex sequencing method
WO2002055725A3 (en) Novel nucleic acids, methods and transformed cells for the modulation of gibberellin production
DE59814359D1 (de) Mikrostrukturierter biosensor, verwendung des biosensors und verfahren zur immobilisierung von biokatalysatoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties